The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β-catenin nuclear translocation in advanced triple-negative breast cancer (TNBC).
 
Jennifer Robinson Diamond
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Casi Pharmaceuticals (Inst); Genentech/Roche (Inst); MedImmune (Inst); Millennium (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst); Scripps Hospital (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takeda; Takeda
 
Pavani Chalasani
No Relationships to Disclose
 
Eleni Andreopoulou
No Relationships to Disclose
 
William Larry Gluck
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Celgene; Genentech/Roche; Merck; Pfizer; Puma Biotechnology; Syndax
Research Funding - Celgene; Corcept Therapeutics; Merck
Other Relationship - G1 Therapeutics
 
Christine Peterson
Employment - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
 
Ely Benaim
Employment - Rexahn Pharmaceuticals
Leadership - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
Honoraria - Rexahn Pharmaceuticals